They won't sell the patent. SPL's business model is to parter with companies once proof-of-concept (ie completion of phase 2 trials) has been established. Deals with partners will always come with some upfront payment followed by milestones/royalties afterwards. The partner will probably then be responsible for phase 3 trials and the costs associated. SPL would be crazy to form a partnership without a patent so I believe this is all a natural progression of a DEP drug lifecycle.
Ann: US patent issued for DEP cabazitaxel nanoparticle, page-18
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |